X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28) 28
index medicus (28) 28
aged (21) 21
male (19) 19
middle aged (19) 19
female (18) 18
oncology (18) 18
hematology (17) 17
multiple myeloma - drug therapy (17) 17
bortezomib (14) 14
thalidomide - administration & dosage (13) 13
treatment outcome (13) 13
multiple myeloma (12) 12
antineoplastic combined chemotherapy protocols - therapeutic use (11) 11
dexamethasone (11) 11
disease-free survival (11) 11
therapy (11) 11
adult (10) 10
multiple myeloma - mortality (10) 10
stem-cell transplantation (10) 10
abridged index medicus (9) 9
boronic acids - administration & dosage (9) 9
lenalidomide (9) 9
pyrazines - administration & dosage (9) 9
recurrence (9) 9
survival (9) 9
thalidomide (9) 9
melphalan - administration & dosage (8) 8
thalidomide - analogs & derivatives (8) 8
aged, 80 and over (7) 7
elderly-patients (7) 7
prednisone - administration & dosage (7) 7
stem cell transplantation (7) 7
boronic acids - adverse effects (6) 6
bortezomib-melphalan-prednisone (6) 6
dexamethasone - administration & dosage (6) 6
kaplan-meier estimate (6) 6
multiple myeloma - therapy (6) 6
pyrazines - adverse effects (6) 6
thalidomide - adverse effects (6) 6
antineoplastic agents - therapeutic use (5) 5
drug administration schedule (5) 5
initial treatment (5) 5
time factors (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (4) 4
induction (4) 4
maintenance therapy (4) 4
melphalan - adverse effects (4) 4
phase-iii (4) 4
prednisone (4) 4
prednisone - adverse effects (4) 4
randomized controlled-trial (4) 4
survival analysis (4) 4
transplantation (4) 4
antineoplastic agents - adverse effects (3) 3
clinical trials (3) 3
combination chemotherapy (3) 3
follow-up studies (3) 3
lenalidomide plus dexamethasone (3) 3
metaanalysis (3) 3
multiple myeloma - complications (3) 3
multiple myeloma - diagnosis (3) 3
multiple-myeloma (3) 3
oral melphalan (3) 3
plus dexamethasone (3) 3
prognosis (3) 3
relapsed multiple-myeloma (3) 3
research (3) 3
retrospective studies (3) 3
salvage therapy (3) 3
thalidomide - therapeutic use (3) 3
transplantation, autologous (3) 3
transplantation, homologous (3) 3
angiogenesis (2) 2
angiogenesis inhibitors - administration & dosage (2) 2
animals (2) 2
antineoplastic agents - administration & dosage (2) 2
autologous transplantation (2) 2
care and treatment (2) 2
chemotherapy (2) 2
chemotherapy, adjuvant (2) 2
clinical trials as topic (2) 2
combination (2) 2
continuous therapy (2) 2
criteria (2) 2
diagnosis (2) 2
disease progression (2) 2
dosage and administration (2) 2
doxorubicin - administration & dosage (2) 2
doxorubicin - analogs & derivatives (2) 2
drug therapy (2) 2
efficacy (2) 2
gene expression regulation, neoplastic (2) 2
genetics & heredity (2) 2
in situ hybridization, fluorescence (2) 2
in-situ hybridization (2) 2
induction chemotherapy - methods (2) 2
leukemia (2) 2
leukemia, myeloid - genetics (2) 2
leukopenia - etiology (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2010, Volume 28, Issue 34, pp. 5101 - 5109
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2014, Volume 32, Issue 7, pp. 634 - 640
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2010, Volume 28, Issue 12, pp. 2077 - 2084
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 10/2015, Volume 33, Issue 30, pp. 3459 - 3466
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 800 - 807
Journal Article
Journal of Hematology and Oncology, ISSN 1756-8722, 01/2019, Volume 12, Issue 1, pp. 4 - 4
Journal Article
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
Expert Review of Hematology, ISSN 1747-4086, 06/2015, Volume 8, Issue 3, pp. 253 - 256
Multiple myeloma (MM) accounts for 1% of all cancers and 13% of all hematologic malignancies. Melphalan-prednisone plus melphalan-prednisone-thalidomide or... 
multiple myeloma | lenalidomide | thalidomide | bortezomib | continuous therapy | maintenance | DEXAMETHASONE | NEWLY-DIAGNOSED MYELOMA | PHASE-III | PREDNISONE | STEM-CELL TRANSPLANTATION | HEMATOLOGY | ELDERLY-PATIENTS | MELPHALAN
Journal Article
Cancer, ISSN 0008-543X, 10/2008, Volume 113, Issue 7, pp. 1588 - 1595
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article